Back to discover
Disease

Schistosomiasis mansoni

Late-stage therapeutic developmentEmerging research
MeSHSchistosomiasis mansoni
1
Publications
5
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial with recent milestones (1 completed or reporting results).
Major developments
Major trial resultsHigh impact
Phase II PK/PD Driven Dose Finding Trial of Praziquantel in Children Under Four
Results posted2026-04-23
Clinical Milestones1View
Results posted 1
Activity timeline1

Clinical trials

5 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
5
All trials
0
Active
3
Late-stage
5
Completed
Recently completed

Phase II PK/PD Driven Dose Finding Trial of Praziquantel in Children Under Four

Phase 2 · Completed · Rhode Island Hospital

Establishing a Female-only Controlled Human Schistosoma Mansoni Infection Model: a Safety and Dose Finding Study (CoHSI2)

N/A · Completed · Leiden University Medical Center

Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology

Phase 4 · Completed · University of Toronto

Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study

Phase 3 · Completed · Pharco Pharmaceuticals

Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Highly Endemic Areas of Northeastern Brazil

Phase 4 · Completed · Oswaldo Cruz Foundation

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes2
  • Biomphalaria1
  • Schistosomiasis mansoni1
Leading journals1
  • BMC genomics1
Leading researchers8
  • Andiego K1
  • Blouin MS1
  • Bollmann SR1
  • Burd R1
  • Calvelo J1
  • Cayton J1
  • Hoffmann FG1
  • Iriarte A1
Affiliations (unnormalised)6
  • Center for Evolutionary and Theoretical Immunology1
  • Centre for Global Health Research1
  • College of Osteopathic Medicine of the Pacific - Northwest1
  • Harvard T.H. Chan School of Public Health1
  • Institute for Genomics1
  • Laboratorio de Biología Computacional1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Schistosomiasis caused by Schistosoma mansoni. It is endemic in Africa, the Middle East, South America, and the Caribbean and affects mainly the bowel, spleen, and liver.

Identifiers
MeSHSchistosomiasis mansoni
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.